Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma

Victor Noriega; Harpreet Kaur; Stephen Devereux; Jennifer Byrne; Robert Marcus; Andrew Haynes; Deborah Yallop; Andrew McMillan; Wendy Ingram; Anjum Khan; Michelle Kenyon; Victoria Potter; Nigel Russell; Ghulam J. Mufti; Antonio Pagliuca

doi:10.1016/j.leukres.2014.03.005

Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma

Victor Noriega^*, Harpreet Kaur, Stephen Devereux, Jennifer Byrne, Robert Marcus, Andrew Haynes, Deborah Yallop, Andrew McMillan, Wendy Ingram, Anjum Khan, Michelle Kenyon, Victoria Potter, Nigel Russell, Ghulam J. Mufti, Antonio Pagliuca

^*Corresponding author for this work

King's College London

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

This is an analysis in 171 patients comparing BEAM-Auto and BEAM-Allo (alemtuzumab)-hematopoietic stem cell transplantation in relapsed follicular lymphoma. BEAM-Allo group had a lower 10 years cumulative incidence of relapse(31.4% vs 55.1%, p = 0.042), a trend to a plateau in survival but no statistical differences in OS or DFS, and a TRM of 24%. When transplanted in CR BEAM-Allo patients had better OS and DFS. Incidence of acute and chronic GVHD was 16.6% and 22%. 29% of BEAM-Allo patients received DLI (all but two remain in CR and alive). Our data supports Allo-HSCT as a potential curative treatment for selected patients with FL.

Original language	English
Pages (from-to)	737-743
Number of pages	7
Journal	Leukemia Research
Volume	38
Issue number	7
DOIs	https://doi.org/10.1016/j.leukres.2014.03.005
Publication status	Published - Jul 2014

Keywords

Follicular lymphoma
Hematopoietic stem cell transplantation
BEAM
Alemtuzumab
NON-HODGKINS-LYMPHOMA
CHRONIC LYMPHOCYTIC-LEUKEMIA
LOW-GRADE
MARROW-TRANSPLANTATION
IBRITUMOMAB TIUXETAN
CONSENSUS CONFERENCE
RANDOMIZED-TRIAL
FREE SURVIVAL
RITUXIMAB
CYCLOPHOSPHAMIDE

Access to Document

10.1016/j.leukres.2014.03.005

Cite this

Noriega, V., Kaur, H., Devereux, S., Byrne, J., Marcus, R., Haynes, A., Yallop, D., McMillan, A., Ingram, W., Khan, A., Kenyon, M., Potter, V., Russell, N., Mufti, G. J., & Pagliuca, A. (2014). Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma. Leukemia Research, 38(7), 737-743. https://doi.org/10.1016/j.leukres.2014.03.005

@article{50424bceb1a446d5b88e7716bc3d7462,

title = "Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma",

abstract = "This is an analysis in 171 patients comparing BEAM-Auto and BEAM-Allo (alemtuzumab)-hematopoietic stem cell transplantation in relapsed follicular lymphoma. BEAM-Allo group had a lower 10 years cumulative incidence of relapse(31.4% vs 55.1%, p = 0.042), a trend to a plateau in survival but no statistical differences in OS or DFS, and a TRM of 24%. When transplanted in CR BEAM-Allo patients had better OS and DFS. Incidence of acute and chronic GVHD was 16.6% and 22%. 29% of BEAM-Allo patients received DLI (all but two remain in CR and alive). Our data supports Allo-HSCT as a potential curative treatment for selected patients with FL.",

keywords = "Follicular lymphoma, Hematopoietic stem cell transplantation, BEAM, Alemtuzumab, NON-HODGKINS-LYMPHOMA, CHRONIC LYMPHOCYTIC-LEUKEMIA, LOW-GRADE, MARROW-TRANSPLANTATION, IBRITUMOMAB TIUXETAN, CONSENSUS CONFERENCE, RANDOMIZED-TRIAL, FREE SURVIVAL, RITUXIMAB, CYCLOPHOSPHAMIDE",

author = "Victor Noriega and Harpreet Kaur and Stephen Devereux and Jennifer Byrne and Robert Marcus and Andrew Haynes and Deborah Yallop and Andrew McMillan and Wendy Ingram and Anjum Khan and Michelle Kenyon and Victoria Potter and Nigel Russell and Mufti, {Ghulam J.} and Antonio Pagliuca",

year = "2014",

month = jul,

doi = "10.1016/j.leukres.2014.03.005",

language = "English",

volume = "38",

pages = "737--743",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "7",

}

Noriega, V, Kaur, H, Devereux, S, Byrne, J, Marcus, R, Haynes, A, Yallop, D, McMillan, A, Ingram, W, Khan, A, Kenyon, M, Potter, V, Russell, N, Mufti, GJ & Pagliuca, A 2014, 'Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma', Leukemia Research, vol. 38, no. 7, pp. 737-743. https://doi.org/10.1016/j.leukres.2014.03.005

TY - JOUR

T1 - Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma

AU - Noriega, Victor

AU - Kaur, Harpreet

AU - Devereux, Stephen

AU - Byrne, Jennifer

AU - Marcus, Robert

AU - Haynes, Andrew

AU - Yallop, Deborah

AU - McMillan, Andrew

AU - Ingram, Wendy

AU - Khan, Anjum

AU - Kenyon, Michelle

AU - Potter, Victoria

AU - Russell, Nigel

AU - Mufti, Ghulam J.

AU - Pagliuca, Antonio

PY - 2014/7

Y1 - 2014/7

N2 - This is an analysis in 171 patients comparing BEAM-Auto and BEAM-Allo (alemtuzumab)-hematopoietic stem cell transplantation in relapsed follicular lymphoma. BEAM-Allo group had a lower 10 years cumulative incidence of relapse(31.4% vs 55.1%, p = 0.042), a trend to a plateau in survival but no statistical differences in OS or DFS, and a TRM of 24%. When transplanted in CR BEAM-Allo patients had better OS and DFS. Incidence of acute and chronic GVHD was 16.6% and 22%. 29% of BEAM-Allo patients received DLI (all but two remain in CR and alive). Our data supports Allo-HSCT as a potential curative treatment for selected patients with FL.

AB - This is an analysis in 171 patients comparing BEAM-Auto and BEAM-Allo (alemtuzumab)-hematopoietic stem cell transplantation in relapsed follicular lymphoma. BEAM-Allo group had a lower 10 years cumulative incidence of relapse(31.4% vs 55.1%, p = 0.042), a trend to a plateau in survival but no statistical differences in OS or DFS, and a TRM of 24%. When transplanted in CR BEAM-Allo patients had better OS and DFS. Incidence of acute and chronic GVHD was 16.6% and 22%. 29% of BEAM-Allo patients received DLI (all but two remain in CR and alive). Our data supports Allo-HSCT as a potential curative treatment for selected patients with FL.

KW - Follicular lymphoma

KW - Hematopoietic stem cell transplantation

KW - BEAM

KW - Alemtuzumab

KW - NON-HODGKINS-LYMPHOMA

KW - CHRONIC LYMPHOCYTIC-LEUKEMIA

KW - LOW-GRADE

KW - MARROW-TRANSPLANTATION

KW - IBRITUMOMAB TIUXETAN

KW - CONSENSUS CONFERENCE

KW - RANDOMIZED-TRIAL

KW - FREE SURVIVAL

KW - RITUXIMAB

KW - CYCLOPHOSPHAMIDE

U2 - 10.1016/j.leukres.2014.03.005

DO - 10.1016/j.leukres.2014.03.005

M3 - Article

SN - 0145-2126

VL - 38

SP - 737

EP - 743

JO - Leukemia Research

JF - Leukemia Research

IS - 7

ER -

Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this